Various immune cell types, such as T cells, NK cells, and macrophages, have been utilized for anti-cancer therapies, resulting in successful outcomes for some cancer patients. Neutrophils are the most abundant immune cells in human circulation. Despite possessing all the characteristics of an ideal anti-cancer effector cell, neutrophils have not been utilized in cancer therapies because IgG-based therapeutic antibodies (Ab) are not able to activate neutrophils efficiently. IgA is superior to IgG in engaging neutrophils through stronger receptor binding and signaling. The project will develop a novel engineered IgA therapeutic platform for oncology and infectious disease indications, leveraging the neutrophil-engaging characteristics of IgA. In proof-of-concept studies for cancer therapeutics, the project aims to target EGFR using the platform, while transcytosis efficiency of the platform will be improved through dimeric IgA (dIgA) engineering for infectious disease applications.